Neurology Central

Spravato® (esketamine) rejected by NICE for treatment-resistant depression


Earlier last year, the US FDA approved a new nasal spray antidepressant termed, Spravato® (esketamine), alongside an oral antidepressant for treatment-resistant depression in adults. However, the National Institute for Health and Care Excellence (NICE) has decided not to recommend the formulation over concerns regarding its clinical and cost–effectiveness.

In response to this, Jennifer Lee (Director of Health Economics, Market Access and Reimbursement at Janssen [High Wycombe, UK]) issued a statement on NICE’s decision stating that: “This negative opinion from NICE is extremely disappointing as it is a decision which may potentially deny patients living with treatment-resistant major depressive disorder access to a much-needed new treatment option.”

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.